Latest news
Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.
AriBio’s POLARIS-AD Phase III trial of AR1001 has completed its 52-week treatment phase. The safety update is useful, but the result that matters is still coming.
Diabetes Tech Moves From Optional Add-On to Earlier Care
Obesity Care Starts Moving Beyond BMI
Canada’s Generic Semaglutide Approval Tests GLP-1 Affordability
India’s Obesity Campaign Dispute Tests the Line Between Awareness and Promotion
England’s Tirzepatide Rollout Shows Approval Is Not Access
Medicare’s GLP-1 Bridge Turns Obesity Coverage Into a Public-Payer Experiment
WHO Makes Obesity Treatment a Global Access Test
Cyberbullying Becomes a Youth Mental Health Policy Target
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.